The Use of Brexpiprazole Combined With a Stimulant in Adults With Treatment-Resistant Attention-Deficit/Hyperactivity Disorder

From the 1Department of Psychiatry, School of Medicine, University of Utah, Psychiatric and Behavioral Solutions, Salt Lake City, UT

2Department of Psychiatry, School of Medicine, University of Rochester, Rochester, NY

3Psychiatric and Behavioral Solutions, Salt Lake City, UT

4Department of Statistics, Penn State University, State College, PA

5Center for Emotional Fitness, Galloway, NJ.

Received February 10, 2022; accepted after revision May 9, 2022.

Address correspondence to: Barrie K. Marchant, MS, 611 N 26th St, Lincoln, NE 68503 (e-mail: [email protected]).

F.W.R. passed away in May 2022.

This publication is based on research using data from data contributor Otsuka Pharmaceutical Co, Ltd, that has been made available through Vivli, Inc. Vivli, Inc, has not contributed to or approved and is not in any way responsible for the contents of this publication.

Researchers who wish to access the data should address their request to Otsuka Pharmaceutical Co, Ltd, at: https://clinical-trials.otsuka.com. These data were generated via protocol #331-08-213. The authors are not able to share the original data.

留言 (0)

沒有登入
gif